Dhalwani Nafeesa N, Fahami Radia, Sathanapally Harini, Seidu Sam, Davies Melanie J, Khunti Kamlesh
Department of Diabetes Research Centre, University of Leicester, Leicester Diabetes Centre, Leicester General Hospital, Leicester, UK.
Leicester Biomedical Research Centre, Leicester, UK.
BMJ Open. 2017 Oct 16;7(10):e016358. doi: 10.1136/bmjopen-2017-016358.
Assess the longitudinal association between polypharmacy and falls and examine the differences in this association by different thresholds for polypharmacy definitions in a nationally representative sample of adults aged over 60 years from England.
Longitudinal cohort study.
The English Longitudinal Study of Ageing waves 6 and 7.
5213 adults aged 60 or older.
Rates, incidence rate ratio (IRR) and 95% CI for falls in people with and without polypharmacy.
A total of 5213 participants contributed 10 502 person-years of follow-up, with a median follow-up of 2.02 years (IQR 1.9-2.1 years). Of the 1611 participants with polypharmacy, 569 reported at least one fall within the past 2 years (rate: 175 per 1000 person-years, 95% CI 161 to 190), and of the 3602 participants without polypharmacy 875 reported at least one fall (rate: 121 per 1000 person-years, 95% CI 113 to 129). The rate of falls was 21% higher in people with polypharmacy compared with people without polypharmacy (adjusted IRR 1.21, 95% CI 1.11 to 1.31). Using ≥4 drugs threshold the rate of falls was 18% higher in people with polypharmacy compared with people without (adjusted IRR 1.18, 95% CI 1.08 to 1.28), whereas using ≥10 drugs threshold polypharmacy was associated with a 50% higher rate of falls (adjusted IRR 1.50, 95% CI 1.34 to 1.67).
We found almost one-third of the total population using five or more drugs, which was significantly associated with 21% increased rate of falls over a 2-year period. Further exploration of the effects of these complex drug combinations in the real world with a detailed standardised assessment of polypharmacy is greatly required along with pragmatic studies in primary care, which will help inform whether the threshold for a detailed medication review should be lowered.
评估多重用药与跌倒之间的纵向关联,并在来自英格兰的全国代表性60岁以上成年人样本中,通过多重用药定义的不同阈值来检验这种关联的差异。
纵向队列研究。
英国老龄化纵向研究第6波和第7波。
5213名60岁及以上成年人。
多重用药者与非多重用药者的跌倒发生率、发病率比(IRR)及95%置信区间。
共有5213名参与者提供了10502人年的随访数据,中位随访时间为2.02年(四分位间距1.9 - 2.1年)。在1611名多重用药参与者中,569人报告在过去2年内至少发生过一次跌倒(发生率:每1000人年175次,95%置信区间161至190);在3602名非多重用药参与者中,875人报告至少发生过一次跌倒(发生率:每1000人年121次,95%置信区间113至129)。多重用药者的跌倒发生率比非多重用药者高21%(调整后的IRR为1.21,95%置信区间1.11至1.31)。使用≥4种药物的阈值时,多重用药者的跌倒发生率比非多重用药者高18%(调整后的IRR为1.18,95%置信区间1.08至1.28);而使用≥10种药物的阈值时,多重用药与跌倒发生率高50%相关(调整后的IRR为1.50,95%置信区间1.34至1.67)。
我们发现近三分之一的总人口使用五种或更多药物,这与两年内跌倒发生率增加21%显著相关。迫切需要在现实世界中对多重用药进行详细的标准化评估,进一步探究这些复杂药物组合的影响,并开展初级保健方面的务实研究,这将有助于确定是否应降低详细药物审查的阈值。